Comparable stake leader
CK Life Sciences Intl (Holdings) Inc
SEC ownership of Transcode Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001829635.
Disclosed value leader
CK Life Sciences Intl (Holdings) Inc
Comparable rows
17/24
Latest evidence
03 Aug 2026
- Public ticker
- RNAZ on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
CK Life Sciences Intl (Holdings) Inc
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
17 of 24
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
CK Life Sciences Intl (Holdings) Inc
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
03 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001829635
- Issuer location
- Boston, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Transcode Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
CK Life Sciences Intl (Ho...
Disclosed value leader
CK Life Sciences Intl (Ho...
Comparable rows
17/24
Latest evidence
03 Aug 2026
13D/G
3/4/5
13F
Lead comparable stake: 84%
7 rows are not safely comparable across share classes.
13D/G row: CK Life Sciences Intl (Holdings) Inc
Showing 1-8 of 24 holder rows.
Quick read
CK Life Sciences Intl (Holdings) Inc leads the comparable SEC ownership view at 84%.
17 of 24 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens CK Life Sciences Intl (Holdings) Inc's linked filing trail.
Comparable ownership
Top 5
CK Life Sciences Intl (Holdings) Inc
84%
Unleash Immuno Oncolytics, Inc.
9.9%
YA II PN, Ltd.
9.9%
Elena Rosa Braci
6.2%
Daniel Eduardo Katzman
5.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 24 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| CK Life Sciences Intl (Holdings) Inc |
13D/G
3/4/5
CK Life Sciences Int'l., (Holdings) Inc. · 10%+ Owner
|
84%
|
$119,295,020
14,134,481 shares
|
$0 | 03 Aug 2026 |
| Unleash Immuno Oncolytics, Inc. |
13D/G
|
9.9%
|
$1,875,000
300,000 shares
|
$0 | 23 Jul 2026 |
| YA II PN, Ltd. |
13D/G
|
9.9%
|
$35,620
101,772 shares
|
$0 | 15 Apr 2026 |
| Elena Rosa Braci |
13D/G
|
6.2%
|
$1,163,975
186,236 shares
|
$0 | 23 Jul 2026 |
| Daniel Eduardo Katzman |
13D/G
|
5.2%
|
$972,569
155,611 shares
|
$0 | 23 Jul 2026 |
| Thomas Joseph Tracy |
13D/G
|
5%
|
$13,300
35,000 shares
|
$0 | 07 Mar 2025 |
| SABBY MANAGEMENT, LLC |
13D/G
|
4.9%
|
$433,482
41,601 shares
|
$0 | 31 Dec 2025 |
| Anson Funds Management LP |
13D/G
|
0.1%
|
$9,494
27,125 shares
|
-$30,224 | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 07 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-11 of 11 reporting-owner rows connected to Transcode Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
11
Largest Forms 3/4/5 holder
DEFJ, LLC
Net 12M change
$0
Latest report
03 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| DEFJ, LLC | 10%+ Owner | $88,340,506 | Mixed | 03 Aug 2026 | ||
| CK Life Sciences Intl (Holdings) Inc | 10%+ Owner | $88,340,506 | Mixed | 03 Aug 2026 | ||
| Anna Moore | 10%+ Owner | $791,920 | Mixed | 08 Jul 2021 | ||
| Robert Michael Dudley | Chief Executive Officer, Director | $91,934 | Filing P/S | 28 Sep 2023 | ||
| Thomas A. Fitzgerald | Interim CEO, CFO, Director | $28,722 | Filing P/S | 14 Jun 2024 | ||
| Elizabeth Czerepak | Director | Mixed | 06 Oct 2025 | |||
| Philippe Calais | Director | Mixed | 14 Jun 2024 | |||
| Magda Marquet | Director | Mixed | 14 Jun 2024 | |||
| Zdravka Medarova | Chief Technology Officer, 10%+ Owner | Mixed | 12 Dec 2022 | |||
| Erik Manting | Director | Mixed | 14 Jun 2024 | |||
| Jack E. Stover | Director | Mixed | 19 Dec 2025 |
Recent insider transactions for Transcode Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Defj, Llc | RNAZ | Common Stock | Conversion of derivative security | 4610.9% | 13,834,441 | 14,134,481 | 03 Aug 2026 | Direct | ||
| Defj, Llc | RNAZ | Common Stock | Conversion of derivative security | 4610.9% | 13,834,441 | 14,134,481 | 03 Aug 2026 | Direct | ||
| Defj, Llc | RNAZ | Series B Non-Voting Convertible Preferred Stock | Conversion of derivative security | -100% | -202 | 0 | 03 Aug 2026 | Direct | ||
| Defj, Llc | RNAZ | Series B Non-Voting Convertible Preferred Stock | Conversion of derivative security | -100% | -202 | 0 | 03 Aug 2026 | Direct | ||
| Defj, Llc | RNAZ | Series A Non-Voting Convertible Preferred Stock | Conversion of derivative security | -100% | -1,181 | 0 | 03 Aug 2026 | Direct | ||
| Defj, Llc | RNAZ | Series A Non-Voting Convertible Preferred Stock | Conversion of derivative security | -100% | -1,181 | 0 | 03 Aug 2026 | Direct |
* marks a reported price that did not pass the local price check.